



NEWS RELEASE



ERS Genomics and Evolve Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

DUBLIN, Ireland, and REINACH, Switzerland, October 27th, 2016 - ERS Genomics Ltd and Evolve (SIX:EVE), a leader in fermentation-based approaches to specialty chemicals, announced today a non-exclusive license agreement which provides Evolve with worldwide access to ERS' CRISPR-Cas9 genome editing intellectual property for use in engineering yeast and fungi for production of ingredients for human and animal health, wellness and nutrition, food and beverages, and other industrial applications. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.

"Genome editing has many applications beyond drug discovery and development and making the CRISPR-Cas9 patents available to industrial biotechnology leaders such as Evolve is a growing and important part of our business. We are thus very pleased to include them in our expanding portfolio of licensees," said **Eric Rhodes**, CEO of ERS Genomics.

"By combining modern genetics with traditional brewing, Evolve tries to overcome some of the challenges in producing natural ingredients for commercial use. Evolve uses proprietary technologies and is committed to gain access to complementary platforms that allow us to enhance the properties of the ingredients we produce, as well as their economics," commented **Neil Goldsmith**, CEO of Evolve.

Dr. Emmanuelle Charpentier's research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna, (Jinek et al., 2012), which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome editing tool.

Financial details of the agreement were not disclosed.

- ends -

About ERS Genomics

ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information, see www.evolva.com. Questions about our approach? Have a look at [our video](#).

Contact ERS Genomics:

MacDougall Biomedical Communications

Mario Brkulj or Dr. Stephanie May

Direct: +49 89 2420 9345 or +49 89 2420 9344

E-Mail: mbrkulj@macbiocom.com or smay@macbiocom.com

Contact Evolva:

Neil Goldsmith, CEO

neilg@evolva.com

+ 41 61 485 2005

Stephan Herrera, Media

stephanh@evolva.com

+ 1 415 794 4005

Paul Verbraeken, IR

paulv@evolva.com

+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.